BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20408960)

  • 21. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
    Barresi V; Buttarelli FR; Vitarelli EE; Arcella A; Antonelli M; Giangaspero F
    Hum Pathol; 2009 Dec; 40(12):1738-46. PubMed ID: 19716156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
    Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
    Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
    Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion.
    Nagaishi M; Suzuki A; Nobusawa S; Yokoo H; Nakazato Y
    Brain Tumor Pathol; 2014 Oct; 31(4):257-64. PubMed ID: 24197863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
    Rodriguez FJ; Scheithauer BW; Jenkins R; Burger PC; Rudzinskiy P; Vlodavsky E; Schooley A; Landolfi J
    Am J Surg Pathol; 2007 Mar; 31(3):351-62. PubMed ID: 17325476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
    Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
    Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
    Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
    Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diversity of glial cell components in pilocytic astrocytoma.
    Tanaka Y; Sasaki A; Ishiuchi S; Nakazato Y
    Neuropathology; 2008 Aug; 28(4):399-407. PubMed ID: 18312545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
    Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
    Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral distribution of 1p loss in oligodendroglial tumors.
    Kros JM; van der Weiden M; Zheng PP; Hop WC; van den Bent MJ; Kouwenhoven MC
    J Neuropathol Exp Neurol; 2007 Dec; 66(12):1118-23. PubMed ID: 18090920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OLIG2 as a specific marker of oligodendroglial tumour cells.
    Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
    Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
    Kim SH; Kim H; Kim TS
    Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype?
    Tanaka Y; Yokoo H; Komori T; Makita Y; Ishizawa T; Hirose T; Ebato M; Shibahara J; Tsukayama C; Shibuya M; Nakazato Y
    Acta Neuropathol; 2005 Jul; 110(1):39-47. PubMed ID: 15906048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
    Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
    J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas.
    Senetta R; Trevisan E; Rudà R; Maldi E; Molinaro L; Lefranc F; Chiusa L; Lanotte M; Soffietti R; Cassoni P
    J Neuropathol Exp Neurol; 2009 Apr; 68(4):425-31. PubMed ID: 19287309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.